Description
PT-141 | Bremelanotide Melanocortin Agonist — Research Grade
PT-141 (Bremelanotide) is a cyclic heptapeptide analogue of alpha-MSH and the first melanocortin-based compound to receive FDA approval for sexual dysfunction. Approved as Vyleesi in June 2019 for HSDD in premenopausal women, it provides a uniquely strong clinical evidence base for research use.
Mechanism of Action
- MC3R/MC4R agonism — activates hypothalamic melanocortin receptors involved in sexual arousal circuitry
- Central (not peripheral) action — works upstream of the vascular events targeted by PDE5 inhibitors, offering a complementary research tool
- No cardiovascular dependency — does not require nitric oxide/cGMP pathway intact (relevant in diabetic neuropathy models)
Research Areas
PT-141 is studied in male and female sexual dysfunction, melanocortin neurocircuitry, obesity (MC4R), and inflammatory pain. Phase III RECONNECT trial (n=1,267) demonstrated significant HSDD improvement vs placebo.
For Research Use Only. Rainbow Peptide supplies PT-141 exclusively for in vitro and laboratory research purposes. Not for human or veterinary use.
Dr. H. Carter –
PT-141 (Bremelanotide) for our melanocortin receptor research. MC4R binding affinity confirmed by our assay. Purity >98.8% by HPLC. COA included full mass spec data. Rainbow Peptide is now our standard source for MC receptor peptides.
A. Lindqvist –
PT-141 purity confirmed at 99% by LC-MS. Our MC1R and MC4R binding panel showed expected relative affinities. Clean COA. Arrived cold with packaging intact. Excellent for melanocortin research.
E. Nwosu –
PT-141 for our sexual dysfunction mechanism research. Purity >98%. Dissolved easily. COA was comprehensive. MC4R response in our cell model was as expected. Turnaround was 2 days. Will reorder.